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1. Introduction 
Glomerulonephritis is a renal disease characterized by inflammation of the glomeruli, i.e., 
small blood vessels, in the kidneys. It may present with isolated hematuria and/or 
proteinuria or as nephritic syndrome, acute renal failure, or chronic renal failure. 
Glomerulonephritis has several different pathological patterns that can be broadly grouped 
into non-proliferative and proliferative types. Non-proliferative types include minimal 
change glomerulonephritis, focal segmental glomerulosclerosis, and membranous 
glomerulonephritis. Proliferative types include IgA nephropathy, post-infectious 
glomerulonephritis, membranoproliferative/mesangiocapillary glomerulonephritis, and 
rapidly progressive glomerulonephritis (Miller et al., 2010). Of the many factors involved in 
the inflammatory response, cytokines are the most important factors that bind to their 
receptors and activate signal transduction pathways. Progress in our understanding of 
inflammatory signaling pathways has led to the identification of the involvement of nuclear 
factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs) such as p38, and Janus 
tyrosine kinase-signal transducer and activator of transcription (JAK-STAT) pathways 
(O’Neill, 2006). The NF-κB and p38 pathways are activated by the stimulation of interleukin-
1 (IL-1) and tumor necrosis factor (TNF). The principal signaling pathways activated by IL-1 
and TNF are the NF-κB and stress-activated MAPK pathways, whereas the JAK-STAT 
pathway is activated by many other cytokines.  
2. STAT family 
JAK-STAT is an important tyrosine kinase pathway activated by almost all cytokines (Ihle, 
2001) that are well known for their role in the progression of renal diseases (Johnson, 1997). 
The STAT family consists of seven members (Table 1). The STAT proteins are unique 
transcription factors containing Src homology (SH) 2 and phosphotyrosine-binding 
domains. The SH2 domain interacts with sites of tyrosine phosphorylation to recruit STATs 
to receptor complexes. Following tyrosine phosphorylation of STATs, dimerization occurs 
between the SH2 domains. Tyrosine phosphorylation around amino acid position 700 
(STAT1, tyrosine 701; STAT3 tyrosine 705) is essential for dimerization of STATs and the 
concomitant nuclear translocation of the dimer (Kaptein et al., 1996; Shuai et al., 1993). The 
basic model of cytokine pathways depends on tyrosine phosphorylation by JAK proteins 
non-covalently bound to specific receptors. The JAK family consists of four members: JAK1, 
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JAK2, JAK3, and Tyk2. In addition, the activity of the C-terminal transactivation domain of 
STATs is at least partially regulated by serine phosphorylation (serine 727 in STAT1 and 
STAT3) that does not involve the JAK protein (Wen et al., 1995). The kinase responsible for 
this serine phosphorylation depends on the signaling pathway and cellular context.  
 
Family 
member 
Chromosomal location
Activating 
cytokines 
Phenotype of knockout mice 
 Murine Human   
STAT1 1 2q12–33 IFNs, IL-6 
Viable, normal development, IFN 
functions eliminated, tumors increased, 
growth control impaired. 
STAT2 10 12q13–14.1 IFNs 
Viable, normal development, IFN 
functions affected. 
STAT3 11 17q11.2–22 IL-6 family 
Embryonic lethal, extraembryonic 
endoderm defects, cell survival impaired. 
STAT4 1 2q12–33 IL-12 
Viable, normal development, IL-12 
functions eliminated, Th1 differentiation 
impaired. 
STAT5A 11 17q11.2–22 Numerous 
Viable, mammary gland deficiency, 
prolactin responsiveness eliminated. 
STAT5B 11 17q11.2–22 Numerous 
Viable, partial loss of growth hormone 
functions. 
STAT6 10 12q13–14.1 IL-4, IL-13 
Viable, normal development, IL-4 
functions eliminated. Th2 differentiation 
impaired. 
Table 1. Properties of STATs.  
3. STAT3 
STAT3 is a member of the JAK-STAT signaling pathway (Zhong et al., 1995). Cytoplasmic 
STAT3 in unstimulated cells is activated by recruitment through the SH2 domain to 
phosphorylated motifs within complexes of cytokine receptors, growth factor receptors, and 
non-receptor tyrosine kinases. Determination of STAT3 functions based on knockout mice 
studies have been difficult because mouse embryos die early in embryogenesis, prior to 
gastrulation (Takeda et al., 1997). STAT3 is essential for the early development of mouse 
embryos. Recently, some studies have succeeded in isolating STAT3 from individual tissues 
by the Cre-loxP method (Akira, 2000), which circumvents the problem of embryonic 
lethality, and revealed the roles of STAT3 in a wide variety of tissues (Table 2). A surprising 
result from such studies has been the identification of a multitude of and sometimes 
contradictory roles of STAT3 in biological processes including cell growth, cell growth 
suppression and apoptosis, and cell motility. The phenotypes resulting from the loss of 
STAT3 in adult tissues include failure of cell survival, impaired apoptosis, loss of negative 
feedback regulation, and impaired cell migration and wound healing (Levy & Lee, 2002). Of 
great current interest is the persistently active STAT3, which occurs in a wide variety of 
human tumors (Bowman & Jove, 1999). Overexpression and/or elevated protein tyrosine 
kinase activity of the epidermal growth factor receptor (EGFR), Src, and other protein 
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kinases is associated with the progression of numerous human cancers. As a consequence, 
growing evidence indicates that abnormal STAT3 signaling in response to hyperactive 
protein tyrosine kinase activity is frequent in human tumors and is associated with the 
progression of oncogenesis (Garcia & Jove, 1998). Furthermore, STAT3 can be converted into 
an oncogene by experimental mutation (Bromberg et al., 1999). A persistently active protein 
is required because introduction of a dominant-negative form of STAT3 into head and neck 
cancer cells or multiple myeloma cells causes apoptosis of recipient cancer cells (Bowman et 
al., 2000). Persistent STAT3 activation in head and neck cancer is associated with mutations 
in EGFR or mutations that result in the production of excess ligands or normal receptors 
(Song & Grandis, 2000). In some multiple myelomas, excess production of IL-6 might be the 
underlying defect (Catlett-Falcone et al., 1999). IL-6-dependent accumulation of long-lived 
plasma cells occurs due to elevated levels of a key regulatory protein, Bcl-xL, a member of 
the Bcl-2 family of proteins that prevent apoptosis. Constitutive activation of STAT3 
signaling, an important component of the IL-6 pathway, directly contributes to the induction 
of Bcl-xL gene expression. Thus, constitutive activation of STAT3 signaling in response to IL-
6 promotes tumor cell survival and malignant progression of multiple myelomas by directly 
inducing expression of a key apoptosis regulatory protein. All these results suggest that 
STAT3 may be essential for many cell functions.  
 
Target tissue Phenotype 
Skin 
Impaired second hair cycle, wound repair and keratinocyte 
migration 
Thymic epithelium Age-dependent thymic hypoplasia, hypersensitivity to stress 
T lymphocytes Impaired IL-6-dependent survival and IL-2Rǂ expression 
Monocytes/neutrophils 
Enhanced inflammatory responses and Th1 differentiation, 
chronic colitis 
Granulocytes Enhanced proliferation owing to impaired negative feedback 
Mammary epithelium Defective apoptosis, delayed mammary involution 
Liver Impaired acute phase response 
Neurons Impaired cell survival 
Table 2. Tissue-specific roles of STAT3 (Levy & Darnell, 2002).  
4. STAT3 in gp130 cytokine signaling 
Several cytokines including IL-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary 
neurotrophic factor, and cardiotrophin share a gp130 subunit that is required to activate 
JAKs and STATs (Stahl et al., 1994). These cytokines are competent to activate STAT3 and 
induce various pleiotrophic responses that include hematopoiesis regulation, immune 
response, and neuronal differentiation (Snick, 1990). gp130-associated kinases JAK1, JAK2, 
and Tyk2 become activated on stimulation, and the cytoplasmic tail of gp130 is 
phosphorylated (Heinrich et al., 1998). STAT3 is recruited to phosphorylated tyrosine 
residues in the YXXQ motif including the tyrosine residue Y705 of gp130, where it is 
activated and dimerized. It subsequently enters the nucleus and regulates gene expression 
(Hirano et al., 2000). STAT3 is essential for gp130-mediated cell survival and G1 to S cell 
cycle transition signals. Both c-myc and pim have been identified as target genes of STAT3 
and together can compensate for STAT3 in cell survival and cell cycle transition. On the 
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other hand, the SH2 domain-bearing protein tyrosine phosphatase (SHP)-2 is recruited to 
the phosphorylated tyrosine residue Y759 in gp130, where it becomes activated and forms a 
complex with adaptor/docking proteins, Gab1 and Gab2, leading to activation of the Ras-
MAPK pathway (Hibi & Hirano, 2000). Several in vitro experiments have shown that SHP-2- 
and STAT3-mediated signal transduction pathways initiated through gp130 are involved in 
growth, differentiation, and gene expression in various cell lines (Fukuda et al., 1996; Hirano 
et al., 2000; Nakajima et al., 1996). SHP-2-mediated ERK/MAPK activation has been 
suggested to play a negative role in STAT3-mediated biological responses (Jain et al., 1998; 
Sengupta et al., 1998). The tyrosine residue Y759 also provides the binding site for the 
suppressor of cytokine signaling 3 (SOCS3) protein that negatively regulates gp130 signals 
(Nicholson et al., 2000; Schmitz et al., 2000). To clarify the roles of SHP-2- and STAT3-
mediated signal transduction pathways in vivo, a series of knock-in mouse lines was 
generated in which gp130-mediated STAT3 or SHP-2 signals were selectively disrupted. 
This disruption was achieved by mutating the tyrosine residues in all YXXQ motifs or the 
tyrosine residue Y759 to phenylalanine (gp130FXXQ/FXXQ and gp130F759/F759 mice, 
respectively) (Ohtani et al., 2000). Analyses of these mice indicated that SHP-2-mediated or 
Y759-dependent signals negatively regulate the biological responses elicited by STAT3-
mediated signals in vivo and that the balance of positive and negative signals generated 
through gp130 is skewed or shifted toward positive STAT3 signaling in gp130F759/F759 mice 
(Fig. 1).  
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Fig. 1. The role of gp130 signals in vivo. A: STAT3/YXXQ and SHP-2/Y759 signals induce 
responses independent of each other. SHP-2/Y759 signals negatively regulate the biological 
responses elicited by STAT3-mediated signals. B: The balance of positive and negative 
signals generated through gp130 is skewed or shifted toward positive STAT3 signaling in 
gp130F759/F759.  
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The SHP-2 signal-deficient mice (gp130F759/F759) were born normally but displayed 
splenomegaly and lymphadenopathy and an enhanced acute phase reaction. In contrast, 
the STAT3 signal-deficient mice (gp130FXXQ/FXXQ) died perinatally, similar to the gp130-
deficient mice. The gp130F759/F759 mice showed prolonged gp130-induced STAT3 
activation. Importantly, these mice in a mixed background with 129 and C57BL/6 
spontaneously develop a rheumatoid arthritis-like autoimmune disease in old age 
(Atsumi et al., 2002). The mice show severe immunological abnormalities, including 
autoantibody production, increased memory/activated T cells, impaired thymic negative 
selection, and peripheral clonal deletion. Development of a rheumatoid arthritis-like 
disease is entirely dependent on mature lymphocytes, but abnormally enhanced 
homeostatic proliferation of CD4 T cells is caused by augmented production of IL-7 by 
non-hematopoietic stromal cells through a STAT3-dependent process (Sawa et al., 2006). 
In mice showing hyperactivation of STAT1/STAT3, T cell recruitment and 
CCL5/RANTES expression is enhanced (McLoughlin et al., 2005). A recent study 
described an IL-17A-triggered positive-feedback loop of IL-6 signaling that involved 
activation of the transcription factors NF-κB and STAT3 in fibroblasts (Ogura et al., 2008). 
Although the underlying mechanisms by which STAT3 regulates tissue fibrosis are not 
fully understood, its activation is required for upregulation of transforming growth factor 
(TGF)-ǃ signaling, activation/proliferation of myofibroblasts, and deposition of 
extracellular matrix proteins (Ma & Zhuang, 2011). All these results suggest that STAT3 
plays an important role in the function of multiple cells.  
5. STAT3 activation in renal cells 
Various factors show STAT3 activation in glomerular mesangial and proximal tubule cells. 
High glucose activates the growth-promoting enzyme JAK2 and its latent STAT 
transcription factors (STAT1, STAT3, and STAT5) and increases TGF-ǃ and fibronectin 
synthesis in mesangial cells (Wang et al., 2002). High glucose-induced tyrosine 
phosphorylation of JAK2, STAT1, and STAT3 as well as TGF-ǃ and fibronectin synthesis are 
abolished by a specific JAK2 inhibitor, AG-490. However, antisense oligonucleotide studies 
have shown that STAT1 activation is more important than STAT3 activation for TGF-ǃ and 
fibronectin synthesis. Angiotensin II induces phosphorylation of JAK2, STAT1, STAT3, 
STAT5A/STAT5B and SHP-2, and angiotensin II-induced phosphorylation is enhanced by 
high glucose levels (Amiri et al., 2002). Angiotensin II-induced growth and collagen IV 
synthesis are also increased under high glucose conditions. Transfection of glomerular 
mesangial cells with JAK2 antisense oligonucleotides blocks angiotensin II-induced growth 
and collagen IV synthesis under both normal and high glucose conditions.  
In renal proximal tubule cells, IL-6 increases phosphorylation of STAT3, phosphoinositide-3 
kinase (PI3K)/Akt, MAPKs, and NF-κB (Lee et al., 2007). IL-6 also stimulates ǂ-methyl-D-
[14C]glucopyranoside uptake, which is indicative of active transport in renal proximal tubule 
cells. The increased uptake can be blocked by pretreatment with a STAT3 inhibitor, a PI3K 
inhibitor, an Akt inhibitor, MAPK inhibitors, and NF-κB inhibitors. High glucose also 
induces activation of Raf-1, p42/p44 MAPK, JAK2, STAT1, and STAT3 (but not STAT5) in 
renal tubular epithelial cells (Huang et al., 2007). Moreover, severe oxidative stress leads to 
tyrosine phosphorylation of STAT3 at Y705 (Arany et al., 2006). This event depends on the 
activation of EGFR and JAK2 and is directly linked to cell death because inhibition of STAT3 
function enables cells to survive severe oxidative stress.  
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6. STAT3 activation in an animal model of glomerulonephritis 
In an animal model of mesangial proliferative glomerulonephritis induced by the injection 
of anti-Thy1.1 antibody, STAT3 is phosphorylated in mesangial cells (Yanagita et al., 2001a). 
STAT3 phosphorylation peaks 8 days after the anti-Thy1.1 injection. Inhibition of growth 
arrest-specific gene 6 by the extracellular domain of its receptor Axl or warfarin abolishes 
STAT3 phosphorylation (Yanagita et al., 2001a) and inhibits mesangial cell proliferation 
(Yanagita et al., 2001b) in vivo. STAT3 can be expressed and activated in the kidneys of rats 
with immune complex glomerulonephritis using BSA as an antigen (Zhang et al., 2005). 
These rats also have increased macrophage infiltration (detected by a surface marker for 
monocytes/macrophages, ED-1), with some cells showing simultaneous expression of p-
STAT3 and ED-1; this may contribute to inflammatory proliferation in the glomeruli and 
accumulation of extracellular matrix proteins. Inhibition of angiotensin-converting enzyme 
(ACE) with fosinopril downregulates STAT3 activation and ED-1 influx, and these effects 
may attenuate renal damage in this model. Hyperglycemia induces activation of JAK2 and 
STATs, including STAT3, in vivo (Banes et al., 2004). Phosphorylation of JAK2, STAT1, 
STAT3, and STAT5 in the glomeruli by streptozotocin (STZ) injection is reduced in rats 
treated with the ACE inhibitor captopril, angiotensin II type 1 receptor antagonist 
candesartan, or AG-490. Furthermore, both candesartan and AG-490 inhibit STZ-induced 
increases in urinary protein excretion. Knockdown of STAT3 activity in vivo prevents 
diabetic glomerulopathy (Lu et al., 2009). While the number of glomeruli does not differ 
between diabetic STAT3 knockdown and reference mice, the diabetic STAT3 knockdown 
mice exhibit significantly less proteinuria, mesangial expansion, glomerular cell 
proliferation, and macrophage infiltration than the diabetic reference mice. Reduction in 
STAT3 activity abrogates the stimulation of inflammatory markers, including IL-6, 
intercellular adhesion molecule-1, and monocyte chemotactic protein (MCP)-1, and blocks 
nuclear translocation of NF-κB. JAK2-STAT3 proteins may be involved in the early kidney 
damage associated with diabetes. AG490 also ameliorates adriamycin-induced nephritic 
syndrome in mice (Li et al., 2007). JAK-STAT signaling is activated in adriamycin 
nephropathy. Phosphorylation of JAK2, STAT1, and STAT3 is significantly inhibited by 
AG490. Proteinuria, glomerulosclerosis, tubulointerstitial lesions, and renal ǂ-smooth 
muscle actin expression are significantly suppressed by AG490 treatment. In addition, 
AG490 inhibits MCP-1 mRNA expression accompanied by reduced interstitial infiltration of 
macrophages and T cells. Activation of JAK-STAT signaling is involved in the progression 
of glomerular diseases with proteinuria. While AG490 inhibits phosphorylation of STAT1 
and STAT3, a novel selective inhibitor of STAT3, S3I-201, has been synthesized. S3I-201 
preferentially inhibits STAT3 DNA-binding activity and diminishes tyrosine 
phosphorylation of STAT3 (Siddiquee et al., 2007). In a mouse model of renal interstitial 
fibrosis induced by unilateral ureteral obstruction, STAT3 was activated and administration 
of S3I-201 attenuated both STAT3 activation and extracellular matrix protein deposition 
following injury (Pang et al., 2010). S3I-201 reduced infiltration of the injured kidney by 
inflammatory cells and suppressed injury-induced expression of fibronectin, ǂ-smooth 
muscle actin, and collagen type 1 proteins, as well as expression of multiple cytokines. 
Furthermore, S3I-201 inhibited proliferation and preferentially induced apoptosis in renal 
interstitial fibroblasts of the obstructed kidney. Inhibition of STAT3 signaling may hold 
therapeutic potential for fibrotic kidney diseases. IL-6 expression is increased in S-(1,2 
dichlorovinyl)-L-cysteine-induced acute renal tubule necrosis (Vaidya et al., 2003) and renal 
ischemia-reperfusion injury (Lemay et al., 2000) in mice. IL-6-deficient mice are resistant to 
www.intechopen.com
 
The Role of STAT3 Activation in Glomerulonephritis 
 
177 
HgCl2-induced acute kidney injury compared with wild-type mice (Nechemia-Arbely et al., 
2008). IL-6 expression and STAT3 activation in renal tubular epithelial cells is significantly 
increased during the development of injury, suggesting active IL-6 signaling. Activation of 
the JAK-STAT pathway in renal and non-renal cells in kidney diseases is shown in Fig. 2.  
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Fig. 2. Activation of the JAK-STAT pathway in renal and non-renal cells in kidney diseases 
(Chuang & He, 2010).  
We have generated a series of knock-in mouse lines with several genetic backgrounds in 
which gp130-mediated STAT3 or SHP-2 signals are selectively disrupted. gp130 is a shared 
receptor of the IL-6 cytokine family (Ohtani et al., 2000). We found that characteristic 
abnormalities in C57BL/6 background gp130F759/F759 mice included not only spontaneous 
polyarthritis but also glomerulonephritis (Fig. 3, only in females) (Tsuji et al., 2009). 
However, spontaneous glomerulonephritis did not develop in DBA/1J background mice, 
indicating that genetic background may affect the development of disease.  
7. STAT3 activation in human glomerulonephritis 
In vitro and animal studies have shown that an increase in STAT3 activity may play a critical 
role in the development of glomerulonephritis. Few studies have investigated the role of 
STAT3 activation in human renal diseases, but one study has identified STAT3 activation in 
the normal human kidney and a marked increase in this activation in many forms of 
glomerulonephritis (Arakawa et al., 2008). The correlation of STAT3 activation with clinical 
and histological parameters suggests that this pathway plays an important role in the 
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pathogenesis of kidney diseases. In addition, mesangial expansion and podocyte loss in the 
glomeruli are important early features of diabetic nephropathy. JAK1, JAK2, and JAK3 as 
well as STAT1 and STAT3 are expressed at higher levels in patients with diabetic 
nephropathy than in control subjects (Berthier et al., 2009). Immunohistochemistry showed 
strong JAK2 staining in glomerular and tubulointerstitial compartments of patients with 
diabetic nephropathy compared with control subjects. These data suggest a direct 
relationship between tubulointerstitial JAK-STAT expression and the progression of kidney 
failure in patients with type 2 diabetic nephropathy and can be used to distinguish 
progressive human diabetic nephropathy. Further studies are needed to clarify the role of 
STAT3 activation in human glomerulonephritis.  
 
 
Fig. 3. Glomerulonephritis in a gp130F759/F759 mouse (female, 12 months). Deposition of 
hyaline droplets in the subendothelial zone is shown.  
8. Conclusions 
The JAK-STAT pathway is a pleiotropic cascade essential to cytokine and growth hormone 
receptor signaling. Signaling through the JAK-STAT pathway is important for the kidney’s 
response to injury in disease. STAT3 activation is observed in an animal model of 
glomerulonephritis and human glomerulonephritis, and the STAT3 pathway inhibition 
ameliorates the renal conditions in some animal models. Further studies are needed to 
clarify the role of STAT3 activation in human glomerulonephritis, but the STAT3 pathway 
inhibition may be one of the potential therapeutic approaches for renal diseases.  
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